Peptides DB
Research-centric peptide and protocol reference hub
Study 12 of 14LL-37 literatureOne health (Amsterdam, Netherlands) · Observational2026

Prevalence, resistance profile, and molecular epidemiology of extended-spectrum β-lactamases producing <i>Escherichia coli</i> from captive giant pandas.

The prevalence of ESBL-producing E. coli in captive giant pandas has risen sharply to 29.0%, with all strains showing high resistance to key antibiotics.

Read at One health (Amsterdam, Netherlands)Add to compare

Where it sits

this study against the rest of the ll-37 corpus
5
Preclinical
5
Observational · this one
0
Open-label
2
Randomised
2
Reviews

Summary and findings

This study measured the prevalence and antibiotic resistance of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli in captive giant pandas. A total of 100 isolates from individual pandas were screened, revealing a prevalence of 29.0%. The isolates exhibited 100.0% resistance to several β-lactam antibiotics.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
29.0% prevalence of ESBL-producing E. coli strains, n=100.n=1002026

Abstract

The authors’ words, as One health (Amsterdam, Netherlands) supplied them

<h4>Background/objective</h4>Extended-spectrum β-lactamase (ESBL)-producing <i>Escherichia coli</i> (<i>E. coli</i>), a bacterium resistant to most β-lactam antibiotics, is a critical clinical global health concern, posing significant health risks to humans and animals including giant pandas. The Chengdu Research Base of Giant Panda Breeding (CRBGP) has the world's largest captive population of giant pandas. This study aimed to investigate the prevalence, antibiotic resistance characteristics, and molecular epidemiology of ESBL-producing <i>E. coli</i> among captive giant pandas at the CRBGP.<h4>Methods</h4>ESBL production was screened in 100 <i>E. coli</i> isolates from 100 individual giant pandas (different ages and sexes) using the Clinical and Laboratory Standards Institute (CLSI) double-disc combination test. ESBL isolates were subjected to antimicrobial susceptibility testing of 34 antibiotics using the Kirby-Bauer disk diffusion susceptibility test (K-B). Whole genome sequencing (WGS) was performed to characterize genotypes, antibiotic resistance genes (ARGs), mobile genetic elements (MGEs), and multilocus sequence typing (MLST), and the molecular epidemiology of the isolates was further investigated using MLST and the goeBURST algorithm.<h4>Results</h4>Twenty-nine ESBL-producing <i>E. coli</i> strains were identified (29.0%, 29/100), representing a marked increase from the 8% prevalence reported during 2020-2021. All 29 isolates exhibited high resistance to β-lactam antibiotics, with 100.0% resistance to amoxicillin, ampicillin, cefazolin, cefuroxime and cefotaxime. A total of 120 different ARG subtypes and 19 ESBL gene subtypes were detected; <i>bla</i> <sub>CTX-M-4</sub> was the most prevalent (100.0%), followed by <i>bla</i> <sub>SHV-1</sub> (96.6%), <i>bla</i> <sub>CTX-M-1</sub> and <i>bla</i> <sub>CTX-M-3</sub> (93.1% each). Analysis of MGEs revealed high carriage rates of <i>IS26</i> (89.7%), <i>intI1</i> (89.7%), and the conjugation-associated gene <i>traA</i> (51.7%). MLST identified 10 sequence types (STs) and one clonal complex (CC1), with ST132 as the founder. ST595 and ST973 were the most common STs (each <i>n</i> = 7).<h4>Conclusions</h4>The prevalence of ESBL-producing <i>E. coli</i> in captive giant pandas at the CRBGP has risen sharply (29.0%), with high-level multidrug resistance (MDR), a large ARG repertoire, and abundant MGEs indicative of strong horizontal gene transfer (HGT) potential. The presence of shared STs with other hosts suggests potential interspecies transmission. These findings underscore the urgent need for enhanced antimicrobial stewardship and continuous One Health surveillance to protect giant pandas and the broader ecosystem.

Background

The study addresses the prevalence and resistance profiles of ESBL-producing E. coli, which pose significant health risks to both humans and animals. Prior research indicated lower prevalence rates of 8% during 2020-2021. Understanding the current resistance patterns in captive giant pandas is crucial for public health and conservation efforts.

Methods

The study utilized a screening of 100 E. coli isolates from 100 individual giant pandas, employing the CLSI double-disc combination test for ESBL production. Antimicrobial susceptibility was tested against 34 antibiotics using the Kirby-Bauer disk diffusion method. Whole genome sequencing was conducted to analyze genotypes, antibiotic resistance genes, and molecular epidemiology.

Results

The primary finding was a 29.0% prevalence of ESBL-producing E. coli strains among the sampled pandas, n=100. All identified strains showed 100.0% resistance to multiple β-lactam antibiotics. The study also reported high carriage rates of mobile genetic elements and identified 10 sequence types through MLST.

Interpretation

The findings indicate a significant increase in the prevalence of ESBL-producing E. coli compared to previous reports. While the statistical significance of the resistance rates is clear, the clinical implications for giant pandas and potential interspecies transmission require further investigation. The study's limitations include its focus on a single population and the speculative nature of interspecies transmission.

Key findings

  • 29.0% prevalence of ESBL-producing E. coli strains, n=100.
  • 100.0% resistance to amoxicillin, ampicillin, cefazolin, cefuroxime, and cefotaxime.
  • 120 different antibiotic resistance gene subtypes detected.
  • 19 ESBL gene subtypes identified, with bla CTX-M-4 at 100.0% prevalence.
  • 89.7% carriage rates of IS26 and intI1 mobile genetic elements.
  • 10 sequence types identified, with ST132 as the founder.

Limitations

  • single-site study at Chengdu Research Base of Giant Panda Breeding
  • potential for interspecies transmission remains speculative
  • no longitudinal data to assess changes over time
  • limited generalizability to wild populations

Elsewhere in the LL-37 corpus

AAdonertinib (FHND9041) versus Afatinib as First-line Treatment for Advanced Non-small-cell Lung Cancer with EGFR Sensitive Mutation (FHND9041-Ⅲ-01): A Multi-centre, Open-label, Randomised Phase 3 Trialbiorxiv-preprint · 2023 · Median PFS was 16.7 months in the adonertinib group and 14.5 months in the afatinib group (HR 0.70, p=0.0087).HumanDA rocky rollout.Science (New York, N.Y.) · 2026BThe interplay between vitamin D status and exerkine signaling: implications for exercise adaptation in athletes: narrative review.Journal of the International Society of Sports Nutrition · 2026HumanBPatterns of health-promoting lifestyles among patients with colorectal cancer: A latent profile analysis.Asia-Pacific journal of oncology nursing · 2026 · Profile 2 associated with psychological frailty (OR = 1.799, P = 0.001)HumanAImmunogenicity and safety of AS03-adjuvanted A/Astrakhan/3212/2020 (H5N8)-like influenza vaccine in adults: Phase 1/2, observer-blinded, randomized trial.Human vaccines & immunotherapeutics · 2026 · Not reported in abstract.HumanBFrom childhood to adult trauma and negative birth experiences: distal and proximal factors associated with childbirth-related posttraumatic stress symptoms.European journal of psychotraumatology · 2026 · CM significantly predicted higher levels of childbirth-related intrusion symptoms, p<0.01.Human